Piper Jaffray maintained an Overweight rating on INSYS Therapeutics (NASDAQ: INSY), and cut the price target to $46.00 (from $49.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Lifshitz & Miller Law Firm Announces Investigation of Aerojet Rocketdyne Holdings, Inc., Brixmor Property Group, Inc., Cardiovascular Systems, Inc., DeVry Education Group Inc., Freeport-McMoRan InFebruary 23, 2016 7:47 PM INSY INVESTORS ALERT: Lieff Cabraser Reminds Investors of Deadline in Class Action Against Insys Therapeutics, Inc.February 23, 2016 5:05 PM Insys Therapeutics (INSY) Tops Q4 EPS by 7cFebruary 23, 2016 6:50 AM Insys Therapeutics Reports Fourth Quarter and Year End 2015 ResultsFebruary 23, 2016 6:50 AM Trading Radar for 2/23: Home Depot (HD), Macy's (M), Ecolab (ECL), Toll Brothers (TOL), First Solar (FSLR) ReportFebruary 22, 2016 3:20 PM